Palladium Nanoparticles/Graphitic Carbon Nitride Nanosheets-Carbon Nanotubes as a Catalytic Amplification Platform for the Selective Determination of 17α-ethinylestradiol in Feedstuffs.

A new kind of nanocomposite, graphitic carbon nitride (g-C3N4)-carbon nanotubes (CNTs), has been synthesized via solid grinding, and followed by thermal polymerization process of melamine and CNTs. Pd nanoparticles were loaded on the as-prepared nanocomposite by the self-assembly method. The Pd/g-C3N4-CNTs nanocomposite exhibited excellent electrocatalytic activity toward the oxidation of 17α-ethinylestradiol (EE2), and compared with other detection methods of EE2, such as HPLC, this detection platform does not need the samples for further purification processing. And this detection platform was compared with HPLC, there is no significant difference between two methods, and the accuracy and precision of the determination of EE2 in feedstuff sample by differential pulse voltammetry (DPV) to a satisfactory level. Thus, the Pd/g-C3N4-CNTs nanocomposite can be used as a signal amplification platform for the detection of EE2 in feedstuffs samples. Under the optimum condition, the current response increased linearly with EE2 concentration from 2.0 × 10-6 ~ 1.5 × 10-4 M with a detection limit of 5.0 × 10-7 M (S/N = 3) by DPV. The Pd/g-C3N4-CNTs showed good reproducibility and excellent anti-interference ability that the relative standard deviation was 3.3% (n = 5). This strategy may find widespread and promising applications in other sensing systems involving EE2.

[Protective actions of acupoint magnetic medicated plaster therapy on hepatic function in the patient of cirrhosis after hepatitis].

OBJECTIVE: To observe the therapeutic effect of acupoint magnetic medicated plaster therapy on cirrhosis after hepatitis. METHODS: One hundred and twenty patients with cirrhosis after hepatitis were randomly divided into 2 groups. The control group (n=60) were treated by the hepatic protective therapy (diammonium glyeyrrhiznate, Silymarin, compound Tanshin, vitamin E), and the treatment group were treated by the liver-protective therapy and acupoint magnetic medicated plaster therapy, for 2-6 therapeutic courses. Clinical symptoms, hepatic function, serum markers of hepatitis B virus and indexes of hepatic fibrosis were investigated. RESULTS: The markedly effective rate and the total effective rate were 65.0% and 95.0% in the treatment group, and 43.3% and 91.7% in the control group, and the serum indexes of hepatic fibrosis decreased signficantly, with significantly diferences (all P < 0.05). CONCLUSION: Acupoint magnetic medicated plaster therapy can improve clinical symptoms, rapidly restore hepatic function, decrease serum indexes of hepatic fibrosis in the patient of cirrhosis after hepatitis.